Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. MSFT
10. IBM

Go back to Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
(NASDAQ: DFTX) Delayed: 36.67 --0 (-0%)
Previous Close $36.67    52 Week High $ 
Open $36.67    52 Week Low $ 
Day High $36.67    P/E N/A 
Day Low $36.67    EPS $ 
Volume 23,532